Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptamer GroupSTU:P0J Gross Margin % is 55.54% as of Dec. 2025, which is 9% above its 10-year median of 50.73. The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, Aptamer Group ranks worse than 60.79% on this metric.
Aptamer Group PLC gross margin has been in long-term decline. The average rate of decline per year is -11.5%.
The historical rank and industry rank for Aptamer Group's Gross Margin % or its related term are showing as below:
STU:P0J'
s Gross Margin % Range Over the Past 10 Years
Min: 20.49 Med: 50.73 Max: 66.53
Current: 48.77
During the past 6 years, the highestGross Margin % of Aptamer Group was 66.53%. The lowest was 20.49%. And the median was 50.73%.
STU:P0J's Gross Margin % is ranked worse than 60.79% of 732
companies
in the Biotechnology industry
Industry Median: 60.915
vs STU:P0J: 48.77
Aptamer Group had a gross margin of 55.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Aptamer Group was -11.50% per year.
Aptamer Group (STU:P0J) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aptamer Group had a gross margin of 55.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Aptamer Group Gross Margin % Related Terms
Aptamer Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Aptamer Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:P0J vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Aptamer Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptamer Group Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptamer Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Aptamer Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aptamer Group (STU:P0J) has a Gross Margin % of 55.54% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Aptamer Group and its competitors. This is near median its historical median of 50.73. Over the past decade, Aptamer Group's Gross Margin % has ranged from 20.49 to 66.53. According to the industry distribution chart, Aptamer Group ranks #445 out of 732 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Aptamer Group's Gross Margin % too high?
Aptamer Group's current Gross Margin % of 55.54% is near median its 10-year median of 50.73. Over the past 10 years, this metric has ranged from a low of 20.49 to a high of 66.53. The Biotechnology industry median Gross Margin % is 60.92. Aptamer Group's value of 55.54% is 8.8% below this industry median. Based on the distribution chart, Aptamer Group ranks #445 out of 732 companies in the Biotechnology industry, which is below the industry midpoint.
How does Aptamer Group's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptamer Group ranks #445 out of 732 companies for Gross Margin %. This places Aptamer Group in the lower half of its industry. The industry median Gross Margin % is 60.92. Aptamer Group's value of 55.54% is 8.8% below this benchmark. Historically, Aptamer Group's own Gross Margin % has ranged from 20.49 to 66.53 over the past decade. While the company's 10-year median is 50.73 vs. the industry median of 60.92, Aptamer Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptamer Group's current Gross Margin % of 55.54% is 8.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Aptamer Group and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptamer Group's current Gross Margin % is 55.54%, which is near median its own 10-year median of 50.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptamer Group stock overvalued right now?
Aptamer Group (STU:P0J) has a current Gross Margin % of 55.54%. The current Gross Margin % is 55.54%, which is near median its 10-year median of 50.73 and 8.8% below the Biotechnology industry median of 60.92. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Aptamer Group (STU:P0J), the current Gross Margin % is 55.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses, Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:P0J has been successfully added to your 
